Faculty

Fawad Aslam, M.B.B.S., M.S.

Clinical Studies

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate and characterize the safety and tolerability of SBT777101, inclusing incidence, nature, and severity of adverse events, incidence and nature of dose-limiting toxicities (DLTs), and change from baseline in targeted vital signs, clinical laboratory tests and ECG parameters.
Evaluation of Citrullinated Antigens in Rheumatoid Arthritis Patient-Matched Synovial Biopsy, Synovial Fluid, and Serum Samples Scottsdale/Phoenix, Ariz.
The purpose of this study is to characterize the presence and level of SBT777101-reactive antigen in synovial biopsy tissue and fluid from both early and late-stage RA patients, who are on different type of medications (including but not limited to TNF-inhibitors. Correlate local levels of antigen with systemic levels measured in serum using matched patient tissue and blood sample, and correlate local and systemic levels of 7101-reactive antigen with ACPA, VICM, and other RA-related serum biomarkers. Also, to evaluate immune cell populations and correlating this with clinical information and levels of antigen.

Tenosynovial Fluid Analysis Scottsdale/Phoenix, Ariz.
The purpose of this study is to describe the tendon lining fluid results that are seen in a wide variety of arthritis conditions, and to find out if ultrasound can predict the amount of inflammation in tendon fluid.
The Mayo Clinic Early Arthritis Cohort Study Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The purpose of this study is to establish a cohort of clinical and biological samples of patients with early rheumatoid arthritis or arthritis like undifferentiated inflammatory arthritis in order to address multiple critical barriers that exist to improved outcomes for patients with RA and other chronic inflammatory arthritides, including: (1) gaps in understanding disease mechanisms; (2) the lack of highly useful diagnostic and prognostic tools; and (3) the unavailability of personalized, targeted therapies for patients with early inflammatory arthritis.